Literature DB >> 2584200

Purification and characterization of the adenosine A2-like binding site from human placental membrane.

K A Hutchison1, I H Fox.   

Abstract

We have purified and characterized the adenosine A2-like binding site from human placental membranes. 5'-N-Ethylcarboxamido[2,8-3H]adenosine ([3H]NECA) binds to this site, with a Kd of 240 nM and a Bmax of 13.0 pmol/mg in human placental membranes. The adenosine A2-like binding site was purified after extraction from placental membranes with 0.1% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid. The purification included ammonium sulfate precipitation and concanavalin A, DEAE-Sephadex, and Sepharose 6B gel filtration chromatographies. The protein was purified 127-fold to homogeneity, with a final specific activity of 1.5-1.9 nmol/mg of protein and a 5.5-8.1% yield of binding activity from the membranes. The purified protein had similar binding properties and an identical potency order for displacement of [3H] NECA by adenosine analogs as the initial membranes. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of purified protein revealed a single band at 98 kDa which coeluted with [3H]NECA binding activity during Sepharose 6B gel filtration chromatography. In 0.1% Triton X-100, the binding complex has a Stokes radius of 70 A, a sedimentation coefficient of 6.9 S, and a partial specific volume of 0.698 ml/g. The detergent-protein complex has a calculated molecular mass of 230 kDa. The estimated frictional ratio is 1.5. The native binding complex appears to consist of a dimer of identical subunits. The function of this ubiquitous protein remains unclear.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2584200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Extracellular ATP stimulates three different receptor-signal transduction systems in FRTL-5 thyroid cells. Activation of phospholipase C, and inhibition and activation of adenylate cyclase.

Authors:  K Sato; F Okajima; Y Kondo
Journal:  Biochem J       Date:  1992-04-01       Impact factor: 3.857

2.  Identification of novel quaternary domain interactions in the Hsp90 chaperone, GRP94.

Authors:  Feixia Chu; Jason C Maynard; Gabriela Chiosis; Christopher V Nicchitta; Alma L Burlingame
Journal:  Protein Sci       Date:  2006-06       Impact factor: 6.725

3.  Structure Based Design of a Grp94-Selective Inhibitor: Exploiting a Key Residue in Grp94 To Optimize Paralog-Selective Binding.

Authors:  Nanette L S Que; Vincent M Crowley; Adam S Duerfeldt; Jinbo Zhao; Caitlin N Kent; Brian S J Blagg; Daniel T Gewirth
Journal:  J Med Chem       Date:  2018-03-20       Impact factor: 7.446

Review 4.  Nomenclature and classification of purinoceptors.

Authors:  B B Fredholm; M P Abbracchio; G Burnstock; J W Daly; T K Harden; K A Jacobson; P Leff; M Williams
Journal:  Pharmacol Rev       Date:  1994-06       Impact factor: 25.468

5.  Purification and characterization of an adenotin-like adenosine binding protein from human platelets.

Authors:  T Fein; E Schulze; J Bär; U Schwabe
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-04       Impact factor: 3.000

6.  Stimulation of human umbilical vein endothelial cell proliferation by A2-adenosine and beta 2-adrenoceptors.

Authors:  V Sexl; G Mancusi; S Baumgartner-Parzer; W Schütz; M Freissmuth
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

7.  Identification of a novel high affinity adenosine binding protein from bovine striatum.

Authors:  A Lorenzen; S Grün; H Vogt; U Schwabe
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-07       Impact factor: 3.000

8.  A2 adenosine receptors in human glomerular mesangial cells.

Authors:  V Stefanović; P Vlahović
Journal:  Experientia       Date:  1995-04-15

9.  The A2 adenosine receptor: guanine nucleotide modulation of agonist binding is enhanced by proteolysis.

Authors:  C Nanoff; K A Jacobson; G L Stiles
Journal:  Mol Pharmacol       Date:  1991-02       Impact factor: 4.436

10.  Different poses for ligand and chaperone in inhibitor-bound Hsp90 and GRP94: implications for paralog-specific drug design.

Authors:  Robert M Immormino; Louis E Metzger; Patrick N Reardon; D Eric Dollins; Brian S J Blagg; Daniel T Gewirth
Journal:  J Mol Biol       Date:  2009-04-08       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.